ORIC Pharmaceuticals Future Growth
Future criteria checks 0/6
ORIC Pharmaceuticals's earnings are forecast to decline at 6.9% per annum while its annual revenue is expected to grow at 69.6% per year. EPS is expected to grow by 4% per annum. Return on equity is forecast to be -49.6% in 3 years.
Key information
-6.9%
Earnings growth rate
4.0%
EPS growth rate
Biotechs earnings growth | 42.4% |
Revenue growth rate | 69.6% |
Future return on equity | -49.6% |
Analyst coverage | Good |
Last updated | 20 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 11 | -185 | -150 | -164 | 9 |
12/31/2025 | N/A | -161 | -123 | -127 | 11 |
12/31/2024 | N/A | -127 | -97 | -89 | 11 |
9/30/2024 | N/A | -120 | -110 | -109 | N/A |
6/30/2024 | N/A | -111 | -100 | -100 | N/A |
3/31/2024 | N/A | -102 | -96 | -95 | N/A |
12/31/2023 | N/A | -101 | -87 | -86 | N/A |
9/30/2023 | N/A | -93 | -78 | -77 | N/A |
6/30/2023 | N/A | -93 | -78 | -76 | N/A |
3/31/2023 | N/A | -90 | -75 | -73 | N/A |
12/31/2022 | N/A | -89 | -77 | -75 | N/A |
9/30/2022 | N/A | -91 | -78 | -76 | N/A |
6/30/2022 | N/A | -85 | -71 | -69 | N/A |
3/31/2022 | N/A | -85 | -69 | -67 | N/A |
12/31/2021 | N/A | -79 | -60 | -60 | N/A |
9/30/2021 | N/A | -84 | -62 | -61 | N/A |
6/30/2021 | N/A | -91 | -59 | -59 | N/A |
3/31/2021 | N/A | -81 | -53 | -52 | N/A |
12/31/2020 | N/A | -74 | -46 | -45 | N/A |
9/30/2020 | N/A | -54 | -35 | -35 | N/A |
6/30/2020 | N/A | -35 | -31 | -30 | N/A |
3/31/2020 | N/A | -30 | -27 | -26 | N/A |
12/31/2019 | N/A | -27 | -24 | -24 | N/A |
12/31/2018 | N/A | -21 | -21 | -21 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4TZ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 4TZ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 4TZ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 4TZ is forecast to have no revenue next year.
High Growth Revenue: 4TZ is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4TZ is forecast to be unprofitable in 3 years.